Oramed’s management and Board of Directors are examining the company’s existing pipeline and conducting a comprehensive review of strategic alternatives. As part of this review process, Oramed will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. Oramed has not set a timetable for completion of this review process. There can be no assurance that this process will result in any such transaction and the company does not intend to disclose additional details unless and until it has entered into a specific transaction. In addition, continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ORMP:
- Largest borrow rate increases among liquid names
- Oramed downgraded to Neutral from Buy at H.C. Wainwright
- Oramed down 73% after phase 3 study of ORMD-0801 did not meet primary endpoint
- Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued
- Oramed downgraded to Hold from Buy at Canaccord
